Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer

OUTLINE: This is a multi-center study. Sample Collection: * Core biopsy * Blood sample 28-day Cycle Treatment Regimen: * Paclitaxel 90 mg/m2 IV D1, 8, and 15 * Avastin 10 mg/kg IV D1 and 15 ECOG Performance Status of 0 or 1 Life Expectancy: Not specified Hematopoietic: * Platelet count \> 100,000/mm³ * Absolute neutrophil count \> 1200/mm³ * PTT \< 1.5 x upper limit of normal * INR \< 1.5 x upper limit of normal Hepatic: * Total bilirubin \< 1.5 mg/dL * SGOT (AST) \< 2 x upper limit of normal Renal: Not specified Cardiovascular: * Clinically significant cardiovascular or cerebrovascular disease including prior myocardial infarction (within 6 months prior to study entry), unstable angina, Grade II or greater peripheral vascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, hypertensive crises, hypertensive encephalopathy or uncontrolled hypertension (SBP\>150, DBP\>100).